Ashkan Golshani: A Step Closer to Developing a Therapeutic Against Platelet-type von Willebrand Disease
Ashkan Golshani, Professor at Carleton University, Co-founder of Designed Biologics, shared on LinkedIn:
”A step closer to developing a therapeutic against Platelet-type von Willebrand Disease (PT-VWD).
I am extremely proud of my team for developing the first-ever drug candidate against PT-VWD, a rare bleeding disorder (published in Blood Advances).
Using our state-of-the-art artificial intelligence-based drug development platform, my lab has developed a peptide that can reverse the phenotype of the mutant protein causing PT-VWD to its wild-type state.
Many thanks to my wonderful collaborators in this project Dr. Maha Othman and Paolo Gresele and all the members of my laboratory, past and present, especially Thomas Kazmirchuk, who spearheaded this project in my lab.
This work provides additional evidence for the applicability of our proprietary AI technology in developing novel therapeutics and diagnostics, moving us closer to replacing traditional monoclonal antibody development with AI-assisted method.”
Read the full article in Blood Advances.
Article: Developing an AI-Generated Peptide Targeting Platelet-type von Willebrand Disease
Authors: Thomas David Daniel Kazmirchuk, Jiashu Wang, Loredana Bury, Emanuela Falcinelli, Calvin Bradbury-Jost, Anastasiia Koziar, Mustafa Al-gafari, Sarah Takallou, William G Willmore, Frank Dehne, Paolo Gresele, Maha Othman, Ashkan Golshani
Stay updated on all scientific advances in the field of bleeding disorders with Hemostasis Today.
-
Oct 7, 2025, 08:27John Chuback - Blood Clots: The Silent Killer
-
Oct 7, 2025, 04:20Nita Radhakrishnan to Present The First Indian Collaborative Data on Hemophilia from the WBDR Registry
-
Oct 6, 2025, 17:51Klaus Mönkemüller Just Released "The EndoCollab Guide for GI Bleeding" For Endoscopists
-
Oct 6, 2025, 08:10Haemophilia Foundation Australia: Animals Can Have Bleeding Disorders Too!
-
Oct 6, 2025, 08:03Peter Libby: Exploring Inflammation in Atherosclerosis: Lessons and Therapeutic Implications
-
Oct 7, 2025, 08:31Brooke Wolford Leads Groundbreaking GWAS Study Identifying Novel Genetic Loci for Venous Thromboembolism
-
Oct 7, 2025, 08:25ImmuneLink LLC Research: Role of Interferon-Gamma (IFN-γ) in Pathophysiology and Management of Deep Vein Thrombosis
-
Oct 7, 2025, 03:56Nathan Connell: Interesting Data in The Management of HAC Has Been Published in Blood from Benoit Guillet and Colleagues
-
Oct 7, 2025, 03:40Nature Communications Study by Amelia Haj and Colleagues Identifies Factor XII as a Safer Target for Anticoagulation
-
Oct 7, 2025, 03:36Lisiena Hysenaj: Excited to Announce the Jeroen Roose Lab’s Latest Publication from Laila Karra Khalil
-
Oct 7, 2025, 03:502025 Nobel Prize: A Milestone for Autoimmunity Research - Awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi
-
Oct 3, 2025, 15:31Anirban Sen Gupta and Andrew Shoffstall Collaboration on Bioinspired Synthetic Platelet Systems for Brain Injury Treatment
-
Oct 3, 2025, 15:07Shai Shen-Orr: Excited to Share that The Human Immunome Project (HIP) Has Launched Its Scientific Partner Network
-
Oct 2, 2025, 04:59Caterina Casari - Prizes for Innovators 2025 Winner!
-
Oct 2, 2025, 04:572025 Innovators Award: Ile de France Région Recognizes 3 Researchers Who Have Committed Themselves to The Innovation
-
Oct 7, 2025, 08:29“48 Poems on 48 Blood Group Systems” - Dr Bhavyaa Beriwal Blends Science and Poetry in Her New Transfusion Medicine Book
-
Oct 7, 2025, 04:35Hema Tallman: During IPAW, We Honor The Unseen Heroes – Plasma Donors
-
Oct 7, 2025, 04:09Svenja Tatjana Barckhausen: Reducing Reliance on U.S. Plasma – Not Just for Europe, But for The World!
-
Oct 7, 2025, 03:58Louise Bannon: Don’t Wait Until You’re Diagnosed to Learn About Blood Clots
-
Oct 6, 2025, 07:40Erin VanDyke: World Thrombosis Day Falls Right At The End Of PA Week, And It’s A Powerful Reminder Of Why I Do What I Do